A Agilent Technologies Inc.

Agilent Automated Workflows at SLAS2025: Connecting with Confidence

(NYSE: A) announced today that it will feature new automated laboratory workflow solutions at the being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.

Automation is becoming increasingly critical for labs as they navigate the competitive landscape. Agilent's automation solutions include sample and standard preparation, auto dilution, sample delivery, and washout. These solutions cover cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry in regulated and non-regulated labs. By automating these tasks, scientists and lab technicians can focus on more important work. Automated sample preparation becomes more manageable, accurate, and consistent, which increases data quality and reduces the time needed to get results, ultimately leading to better decisions.

“Connecting automated solutions to your workflows allows for current manual processes to be a thing of the past, significantly boosting lab productivity, making lab managers’ days easier and giving back time to focus on other tasks,” stated Lars Kristiansen, general manager of Agilent’s Automation Solutions Business. “SLAS is the perfect platform for us to showcase how our cutting-edge automation solutions push the boundaries of what's possible. We're dedicated to delivering innovative workflow solutions that advance automation and drive customer success.”

SLAS attendees are invited to visit exhibit booth #1529 to discover how Agilent's automation solutions can confidently connect and enhance their labs. Highlighted innovations will include:

  • ‒ The NovoCyte Opteon boasts up to 5 lasers and 73 detectors, a proprietary optics design, and advanced electronics, enabling it to deliver data with high resolution and sensitivity.
  • ‒ The SureSelect Cancer CGP Assay offers comprehensive genomic profiling for solid tumors, detecting various somatic variants and immuno-oncology biomarkers.
  • ‒ Agilent has partnered with ePrep to offer streamlined end-to-end workflow solutions for GC/MS and LC/MS analyses.
  • ‒ Agilent Avida offers high-performance target enrichment for DNA sequencing, optimized for sensitive variant detection and streamlined workflows.

A Solutions Spotlight Presentation “Revolutionizing Viral Infectivity Assays: High-Resolution Automated Cell Imaging Meets AI/ML Analysis” will be held Monday, January 27, from 11:30 AM - 11:50 AM PT in the SLAS Solutions Spotlight Theater (Booth #2907) highlighting the platform. Presenters include Ilya Goldberg, Ph.D., Chief Scientific Officer at , and Joe Clayton, Ph.D., Director of Application Development and Technical Marketing, in the Cell Analysis Division at Agilent.

Additionally Agilent will participate in a roundtable discussion entitled “Robotic automation is the gateway to the Lab of the Future,” hosted by . The conversation will highlight how robots can unlock new possibilities in the lab, and explore some of the challenges that can be solved using robots. The roundtable will be held on Tuesday, January 28, from 8:30 AM - 10:00 AM PT in Room #26A at the conference venue, and is open to all SLAS attendees.

Agilent is a proud Diamond Sponsor of the SLAS2025 International Conference & Exhibition, highlighting Agilent's commitment to advancing laboratory automation and life sciences discovery.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on and .

EN
24/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch